| UniProt ID | IPIL1_HUMAN | |
|---|---|---|
| UniProt AC | Q6GPH6 | |
| Protein Name | Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 | |
| Gene Name | ITPRIPL1 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 555 | |
| Subcellular Localization |
Membrane Single-pass type I membrane protein . |
|
| Protein Description | ||
| Protein Sequence | MNVDAEASMAVISLLFLAVMYVVHHPLMVSDRMDLDTLARSRQLEKRMSEEMRLLEMEFEERKRAAEQRQKAENFWTGDTSSDQLVLGKKDMGWPFQADGQEGPLGWMLGNLWNTGLFCLFLVFELLRQNMQHEPAFDSSSEEEEEEVRVVPVTSYNWLTDFPSQEALDSFYKHYVQNAIRDLPCTCEFVESFVDDLIEACRVLSRQEAHPQLEDCLGIGAAFEKWGTLHETQKFDILVPIVPPQGTMFVLEMRDPALGRRCGCVLVESECVCKREKLLGDVLCLVHHHRDPSAVLGKCSSSIKAALCTGFHLDVCKTVQWFRNMMGNAWALVAHKYDFKLSLPPSTTSCKLRLDYRSGRFLSIHLVLGVQREDTLVYLVSQAPDQEQLTSVDWPESFVACEHLFLKLVGRFAPENTCHLKCLQIILSLRQHQSLPHGASRPILTSYHFKTALMHLLLRLPLTDWAHNMLSQRLQDILWFLGRGLQQRSLHHFLIGNNFLPLTIPIPKTFRNAEPVNLFQHLVLNPKAHSQAVEEFQNLLTQVKTLPHAPLAAAP | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 (in isoform 2) | Phosphorylation | - | 40.14 | 24043423 | |
| 3 (in isoform 2) | Phosphorylation | - | 7.72 | 24043423 | |
| 5 (in isoform 2) | Phosphorylation | - | 15.24 | 24043423 | |
| 6 (in isoform 2) | Phosphorylation | - | 36.49 | 24043423 | |
| 7 (in isoform 2) | Phosphorylation | - | 13.31 | 24043423 | |
| 9 (in isoform 2) | Phosphorylation | - | 4.44 | 24043423 | |
| 10 (in isoform 2) | Phosphorylation | - | 7.94 | 24043423 | |
| 16 (in isoform 2) | Phosphorylation | - | 5.09 | 24043423 | |
| 21 (in isoform 2) | Phosphorylation | - | 7.85 | 24043423 | |
| 29 (in isoform 2) | Phosphorylation | - | 7.68 | 24043423 | |
| 38 (in isoform 2) | Phosphorylation | - | 3.58 | 24043423 | |
| 41 | Phosphorylation | DLDTLARSRQLEKRM CHHHHHHHHHHHHHH | 20.83 | - | |
| 49 | Phosphorylation | RQLEKRMSEEMRLLE HHHHHHHHHHHHHHH | 34.14 | 27174698 | |
| 63 | Ubiquitination | EMEFEERKRAAEQRQ HHHHHHHHHHHHHHH | 50.06 | 29967540 | |
| 71 | Ubiquitination | RAAEQRQKAENFWTG HHHHHHHHHHHCCCC | 60.91 | 29967540 | |
| 77 | Phosphorylation | QKAENFWTGDTSSDQ HHHHHCCCCCCCCCE | 22.50 | 19367720 | |
| 79 | Ubiquitination | AENFWTGDTSSDQLV HHHCCCCCCCCCEEE | 35.72 | 29967540 | |
| 81 | Ubiquitination | NFWTGDTSSDQLVLG HCCCCCCCCCEEEEC | 36.34 | 22817900 | |
| 81 | Ubiquitination | NFWTGDTSSDQLVLG HCCCCCCCCCEEEEC | 36.34 | 21906983 | |
| 81 | Phosphorylation | NFWTGDTSSDQLVLG HCCCCCCCCCEEEEC | 36.34 | 19367720 | |
| 82 | Ubiquitination | FWTGDTSSDQLVLGK CCCCCCCCCEEEECC | 31.31 | 22817900 | |
| 89 (in isoform 1) | Ubiquitination | - | 41.25 | 21906983 | |
| 89 | Ubiquitination | SDQLVLGKKDMGWPF CCEEEECCCCCCCCC | 41.25 | 22817900 | |
| 90 | Ubiquitination | DQLVLGKKDMGWPFQ CEEEECCCCCCCCCC | 51.66 | 22817900 | |
| 97 (in isoform 2) | Ubiquitination | - | 34.17 | 21906983 | |
| 97 | Ubiquitination | KDMGWPFQADGQEGP CCCCCCCCCCCCCCC | 34.17 | 22817900 | |
| 98 | Ubiquitination | DMGWPFQADGQEGPL CCCCCCCCCCCCCCC | 24.23 | 22817900 | |
| 140 | Phosphorylation | HEPAFDSSSEEEEEE CCCCCCCCCHHHHHC | 43.54 | 23879269 | |
| 141 | Phosphorylation | EPAFDSSSEEEEEEV CCCCCCCCHHHHHCC | 53.64 | 23879269 | |
| 266 | Ubiquitination | GRRCGCVLVESECVC CCCCCEEEEECCCEE | 4.04 | - | |
| 266 | Ubiquitination | GRRCGCVLVESECVC CCCCCEEEEECCCEE | 4.04 | 22505724 | |
| 269 | Ubiquitination | CGCVLVESECVCKRE CCEEEEECCCEECHH | 28.90 | - | |
| 274 | Ubiquitination | VESECVCKREKLLGD EECCCEECHHHHHHC | 43.10 | 22505724 | |
| 277 | Ubiquitination | ECVCKREKLLGDVLC CCEECHHHHHHCEEH | 53.71 | - | |
| 282 | Ubiquitination | REKLLGDVLCLVHHH HHHHHHCEEHHHCCC | 3.74 | 22505724 | |
| 290 | Ubiquitination | LCLVHHHRDPSAVLG EHHHCCCCCHHHHHH | 53.85 | - | |
| 298 | Ubiquitination | DPSAVLGKCSSSIKA CHHHHHHHCCHHHHH | 27.12 | - | |
| 451 | Phosphorylation | LTSYHFKTALMHLLL CCHHHHHHHHHHHHH | 24.87 | 22210691 | |
| 509 | Phosphorylation | LTIPIPKTFRNAEPV EECCCCCCCCCCCCC | 23.60 | - | |
| 519 | Ubiquitination | NAEPVNLFQHLVLNP CCCCCCHHHHHHCCH | 3.47 | - | |
| 527 | Ubiquitination | QHLVLNPKAHSQAVE HHHHCCHHHHHHHHH | 58.62 | - | |
| 536 | Ubiquitination | HSQAVEEFQNLLTQV HHHHHHHHHHHHHHH | 3.55 | 29967540 | |
| 536 | Ubiquitination | HSQAVEEFQNLLTQV HHHHHHHHHHHHHHH | 3.55 | - | |
| 544 | Ubiquitination | QNLLTQVKTLPHAPL HHHHHHHHCCCCCCC | 34.23 | 29967540 | |
| 552 | Ubiquitination | TLPHAPLAAAP---- CCCCCCCCCCC---- | 10.66 | 29967540 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of IPIL1_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of IPIL1_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of IPIL1_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| SGTA_HUMAN | SGTA | physical | 21516116 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Phosphorylation analysis of primary human T lymphocytes usingsequential IMAC and titanium oxide enrichment."; Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.; J. Proteome Res. 7:5167-5176(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-77 AND SER-81, AND MASSSPECTROMETRY. | |